Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, and other microbes develop resistance to the medicines used to treat infections and diseases. This resistance is often caused by improper or overuse of antimicrobial drugs. AMR leads to prolonged illness and hospital stays, and increased mortality and healthcare costs. The Centers for Disease Control and Prevention (CDC) cites AMR as one of the greatest public health challenges today. In the U.S., more than 2.8 million people contract an antimicrobial-resistant infection annually, leading to over 35,000 deaths annually.1 Estimates show that, in 2019, over 1.27 million deaths globally could be attributed to AMR bacterial infections2 and by 2050, 10 million lives annually and $100 trillion in economic output could be lost to AMR.3 Low- and middle-income countries will be most affected. Combating AMR requires reduced antibiotics usage; improved infection prevention and control (IPC) measures, especially in healthcare facilities; greater access to water, sanitation and hygiene (WASH); and development of new medicines and tools. Unfortunately, research and development (R&D) has not kept pace with rising resistance. The market for new medicines and tools is not profitable, necessitating federal policies